Annals of Hematology

, Volume 91, Issue 5, pp 705–714

Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens

  • Naoe Goto
  • Hisashi Tsurumi
  • Hideko Goto
  • Yoriko Ino Shimomura
  • Senji Kasahara
  • Takeshi Hara
  • Ichiro Yasuda
  • Masahito Shimizu
  • Nobuo Murakami
  • Takeshi Yoshikawa
  • Kenji Fukuno
  • Takeshi Takahashi
  • Yusuke Kito
  • Tsuyoshi Takami
  • Hisataka Moriwaki
Original Article

DOI: 10.1007/s00277-011-1363-4

Cite this article as:
Goto, N., Tsurumi, H., Goto, H. et al. Ann Hematol (2012) 91: 705. doi:10.1007/s00277-011-1363-4

Abstract

Serum concentration of soluble interleukin-2 receptor (sIL-2R) predicts the clinical outcome of patients with aggressive non-Hodgkin's lymphoma treated with the cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen without rituximab. In the present study, we aim to re-assess the prognostic significance of serum sIL-2R for diffuse large B cell lymphoma (DLBCL) patients treated with CHOP plus rituximab and to assess sIL-2R with subtype of DLBCL, such as GCB type and non-GCB type. Two hundred and thirty-three patients with DLBCL were enrolled between December 2002 and March 2008. To evaluate serum levels of sIL-2R, venous blood samples were drawn from patients immediately before initiation of treatment. Serum sIL-2R was determined by sandwich enzyme-linked immunosorbent assay. The 5-year overall survival (OS) rates for patients with sIL-2R levels of ≥2,000 (110 cases) and <2,000 U/mL (123 cases) were 54.2% and 89.0% (P < 0.0001), respectively. Multivariate analysis using the proportional-hazards model revealed that serum sIL-2R (P = 0.0099) and extranodal involvement sites (P = 0.0392) were independent prognostic factors for OS and that clinical stage (P = 0.0168), performance status (P = 0.0181), sIL-2R (P = 0.0232), and LDH (P = 0.0316) were independent prognostic factors for progression-free survival in sIL-2R and every factor of the International Prognostic Index. Serum sIL-2R might be a useful prognostic factor for DLBCL patients in the rituximab era.

Keywords

Soluble interleukin-2 receptor (sIL-2R) R-CHOP DLBCL 

Supplementary material

277_2011_1363_Fig4_ESM.jpg (78 kb)
Supplementary figure

OS (a) and PFS (b) curves for patients with DLBCL treated with CHOP with serum sIL-2R ≥2,000 U/mL and for those with sIL-2R <2,000 U/mL (P < 0.0001 for OS; P < 0.0001 for PFS) (JPEG 78 kb)

277_2011_1363_MOESM1_ESM.tif (1.5 mb)
High-resolution image (TIFF 1,520 kb)

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Naoe Goto
    • 1
    • 4
  • Hisashi Tsurumi
    • 1
  • Hideko Goto
    • 2
  • Yoriko Ino Shimomura
    • 1
  • Senji Kasahara
    • 1
  • Takeshi Hara
    • 1
  • Ichiro Yasuda
    • 1
  • Masahito Shimizu
    • 1
  • Nobuo Murakami
    • 1
  • Takeshi Yoshikawa
    • 3
  • Kenji Fukuno
    • 2
  • Takeshi Takahashi
    • 2
  • Yusuke Kito
    • 4
  • Tsuyoshi Takami
    • 4
  • Hisataka Moriwaki
    • 1
  1. 1.First Department of Internal MedicineGifu University Graduate School of MedicineGifuJapan
  2. 2.Second Department of Internal MedicineGifu Municipal HospitalGifuJapan
  3. 3.Department of Internal MedicineKisogawa HospitalAichiJapan
  4. 4.Department of ImmunopathologyGifu University Graduate School of MedicineGifuJapan

Personalised recommendations